CRO league tables: Competition, privatization and acquisition
This article was originally published in Scrip
Executive Summary
Over the past 12 months, the CRO industry has continued to make its mark in drug development. The IPO of the largest player in the market and the merger of two competitor companies are just two of the brushstrokes that make up the CRO portrait to date. Jo Shorthouse steps back and takes in the view.
You may also be interested in...
Coming Of Age: Pharma’s Influencer Marketing Matures
Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.
Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy
Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.